Table 1.
Genes related to adaptive immune responses in CVID patients before and after IVIg treatment.
Table 2.
Genes related to innate immune responses in CVID patients before and after IVIg treatment.
Figure 1.
Genes modulated by IVIg infusion.
A. Graphical representation of the expression of the 23 genes returned to the levels of normal controls after IVIg infusion. B. FC expression, before and after therapy, of the genes represented in panel A with the corresponding colours.
Figure 2.
Real time RT-PCR of some modulated genes confirms the results of gene array analysis.
Genes selected for validation in PBMC of CVID patients before IVIg treatment. IL8, RGS1 and CCR3 transcripts were increased, whereas TNFRSF17 transcript was decreased in CVID patients when compared to healthy donors. Relative expression levels were calculated for each sample after normalization against the housekeeping genes 18s rRNA, beta-actin and GAPDH. Experiments have been conducted in triplicates. Housekeeping genes: blue bar = 18s rRNA; magenta bar: beta-actin; yellow bar: GAPDH.
Figure 3.
Flow cytometric analysis of T and B cell populations in CVID patients before and after IVIg infusion.
Data are representative of all the subjects studied. A and B panels show the percentages of CD4+ and CD8+T cell populations before and after IVIg infusion, respectively. Percentages of naïve B cells, centrocytes and switched memory B cells before and after IVIg infusion are displayed in C vs D, E vs F and G vs H panels, respectively.
Figure 4.
Serum levels of selected soluble mediators in CVID patients before and after IVIg infusion.
The histogram represents the mean of the results obtained in 30 patients. Results are expressed in pg/ml. p values calculated using the Student's t-test for paired samples.